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eft Anterior Descending
oronary Artery
evascularization
atient-Tailored Therapy?*
ntonio Abbate, MD, George W. Vetrovec, MD, FACC
ichmond, Virginia
oronary revascularization continues to be a useful thera-
eutic tool in the management of selected patients with
ymptoms or significant myocardium at ischemic jeopardy.
he Remote Medical versus the 10-year CABG (Coronary
rtery Bypass Surgery) trials emphasized the greater sur-
ival benefit in patients with worse anatomic and ischemic
isk (1). Patients with the greatest myocardial ischemia,
oorest left ventricular function, and most anatomic coro-
ary disease tended to receive the greatest benefit (2). With
he advent of percutaneous coronary intervention (PCI),
here was a general belief that, in patients with less severe
isease, PCI was a reasonable alternative strategy to coro-
ary artery bypass grafting (CABG), even in the initial
alloon era. Conversely, for patients with more complex
isease, CABG generally was considered more likely to
rovide the best outcomes. This approach has continued
nto the present.
See page 483
However, because of recognized additional risk for the
eft anterior descending artery (LAD), the single-vessel PCI
lgorithm has been challenged frequently regarding the best
trategy for this specific vessel. Remarkably, these concep-
ual strategies are based on a paucity of trial data covering
early 30 years. Furthermore, the technology for CABG,
CI, and even the quality of medical therapeutics has
ontinued to evolve, often at a pace that tends to make
ulticenter randomized trials of debatable impact by the
ime long-term follow-up is completed.
One popular way to address relatively small trial data
ncompassing a changing field is to perform a meta-
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.f
From the VCU Pauley Heart Center, Virginia Commonwealth University, Rich-
ond, Virginia.nalysis. In this issue of the Journal, Kapoor et al. (3)
escribe the results of such an analysis, examining compar-
tive outcomes for PCI versus CABG in patients with
solated LAD disease. In their analysis of 9 randomized
ontrol trials (RCTs) including 1,210 patients with isolated
ingle-vessel LAD disease, treatment strategies varied
reatly for PCI from balloon angioplasty to stents (although
nly one small trial included drug-eluting stents [DES]) as
ell as for CABG, which included standard on-pump
urgery to limited thoracotomy using off-pump techniques.
Nevertheless, the accurate statistical analysis performed
y the authors showed a virtual lack of heterogeneity among
he different trials, suggesting that the overall balance
etween CABG and PCI has remained stable over the years
espite significant changes in both fields. Indeed on analy-
is, there was no difference in rates of mortality for either
evascularization strategy at 30 days, 1 year, and 5 years.
pecific, adverse procedure-related events were not different
etween revascularization strategies, including the incidence
f myocardial infarction and stroke. The use of CABG
ppeared to have a greater incidence of procedure-associated
rrhythmias, whereas bleeding risks were not different
etween treatments, although for these latter 2 events, there
ere only a small number of studies reporting these events.
Not surprisingly, those patients undergoing CABG had
onger hospital stays by 3 days, but angina relief was
ignificantly better, favoring CABG at years 1 and 5,
hereas the need for repeat revascularization was signifi-
antly less for CABG compared with PCI at the same time
ntervals. No data are given on the composite risk of major
dverse coronary and cerebral events for this analysis, but
ne could speculate that, based on the difference in repeat
evascularization, a combined-risk end point might have
avored the use of CABG as the lower-risk procedure.
The impact of these findings no doubt will be debated.
he most confident conclusions are equivalent death rates
nd greater need for revascularization in the PCI group. In
eneral, this is what we have learned to expect. Added to
hese findings, the recognized greater acute morbidity for
ABG supported in this study by an increased hospital stay,
he therapies may be considered equal, or perhaps favoring
CI acutely and CABG late. But much is missing for
linical decision-making. The population tended to be
oung, with few patients who were 75 years or older, a low
ncidence of reduced ejection fractions, significantly fewer
omen, and only 1 study in which DES was used. There
lso was great variation in the incidence of unstable angina
n the studies. Thus, although we can be comforted by
imilar mortality in the analysis, this only applies to the
opulation studied. Contemporary revascularization con-
ronts many more complex clinical and anatomic subsets.
Although RCTs give reassurance of patient equivalency,
he requirement to randomize may include patients eligible
or either therapy but not ideal for one or the other
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493reatment based often on coronary anatomy or perhaps less
ften on patient characteristics such as diabetes. These
ubtle variations which are not quantified in RCTs always
aise concern regarding the applicability of the trial results to
linical practice. An example is the Emory EAST (Emory
ngioplasty versus Surgery Trial) registry (4), in which
atients who were eligible for randomization but who were
ot randomized and were ultimately treated based on
ndividualized physician decisions had better overall out-
omes than did the randomized patients. This result sug-
ests that individualized patient decisions can make a
ifference because ideal decisions rest on far more factors
han just “eligibility” for either revascularization strategy.
he best therapeutic intervention for a 45-year-old airline
ilot with single-vessel LAD disease may be significantly
ifferent than for a 78-year-old woman with global left
entricular dysfunction, diabetes, and renal insufficiency,
ven though both revascularization strategies are theoreti-
ally acceptable for each patient from a strictly randomiza-
ion standpoint. Likewise, specific anatomic findings, such
s a small distal LAD for grafting or an ostial LAD lesion
ith left main disease involvement, when considering PCI
ay make each case more ideally amenable to the opposite
herapy, even though each circumstance is potentially treat-
ble by an assigned strategy.
None of these examples is meant to negate the value of
CTs or the meta-analysis reported by Kapoor et al. (3).
he examples do, however, emphasize that although the
eta-analysis gives reassurance in terms of equivalent sur-
ival in a general population, considerable physician input
emains necessary to best manage patients with isolated
AD disease. Conversely, registry data are likewise often
awed by greater-risk or older patients selected for PCI who
re perhaps not ideal, either to avoid being turned down or
lready having been turned down for a presumed higher-risk
ABG procedure. There are no asterisks in these databases
or such circumstances.
The issue of patient composition affecting registry out-
ome data has been recently highlighted by the SYNTAX
CI Registry (5). The PCI registry was populated with
igh-risk patients turned down for CABG. The resultant
palliative” PCI was associated with, not unexpectedly, poor
utcomes because of patients with multiple, high-risk co-
orbidities. In contrast, the CABG registry of PCI turn-
owns was comprised of lower-risk patients turned down
redominantly for unfavorable anatomy for PCI, not for
dverse systemic abnormalities. Successful stenting of a
ymptomatically culprit lesion, unresponsive to medical
reatment may improve a patient’s quality of life (a worth-
hile clinical accomplishment) despite a significant risk for
ubsequent morbid events. Thus, caution must be exercised
n interpreting outcomes of comparative registries unless bne is certain of the distribution of patient profiles and the
oals of therapy.
During the coming years, the ultimate additional benefit
f DES is yet to be realized. To the extent that late
hrombosis is limited and less restenosis leads to better late
utcomes (lower rates of late revascularization will poten-
ially lead to lower late event rates secondary to less repeat
rocedures) (6), DES may have a significant impact on
mproving PCI outcomes in isolated LAD disease. But
gain, these results will need to be modulated by more
aried patient and anatomic populations to be able to
ccurately predict the best strategy for individual patient
ircumstances.
onclusions
onsidering the equivalent survival with CABG and PCI,
solated LAD revascularization should be dictated by ana-
omic and patient characteristics and preferences. Individ-
alizing strategies has the greatest opportunity to provide
ptimal patient outcomes.
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